BR112015009070A2 - proteína de fusão ou coquetel de antígenos; uso de uma proteína de fusão ou um coquetel de antígenos; vacina; e método para imunizar um animal, que inclui um ser humano, contra tuberculose causada por microbactérias virulentas - Google Patents

proteína de fusão ou coquetel de antígenos; uso de uma proteína de fusão ou um coquetel de antígenos; vacina; e método para imunizar um animal, que inclui um ser humano, contra tuberculose causada por microbactérias virulentas

Info

Publication number
BR112015009070A2
BR112015009070A2 BR112015009070A BR112015009070A BR112015009070A2 BR 112015009070 A2 BR112015009070 A2 BR 112015009070A2 BR 112015009070 A BR112015009070 A BR 112015009070A BR 112015009070 A BR112015009070 A BR 112015009070A BR 112015009070 A2 BR112015009070 A2 BR 112015009070A2
Authority
BR
Brazil
Prior art keywords
fusion protein
cocktail
mycobacterium
antigens
virulent
Prior art date
Application number
BR112015009070A
Other languages
English (en)
Portuguese (pt)
Inventor
Aagaard Claus
Rosenkrands Ida
Andersen Peter
Thi Kim Thanh Hoang Truc
Original Assignee
Statens Seruminstitut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Seruminstitut filed Critical Statens Seruminstitut
Publication of BR112015009070A2 publication Critical patent/BR112015009070A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112015009070A 2012-10-23 2013-10-18 proteína de fusão ou coquetel de antígenos; uso de uma proteína de fusão ou um coquetel de antígenos; vacina; e método para imunizar um animal, que inclui um ser humano, contra tuberculose causada por microbactérias virulentas BR112015009070A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201200652 2012-10-23
DKPA201200654 2012-10-23
DKPA201200653 2012-10-23
DKPA201300477 2013-08-23
PCT/DK2013/000070 WO2014063704A2 (en) 2012-10-23 2013-10-18 M. tuberculosis vaccines

Publications (1)

Publication Number Publication Date
BR112015009070A2 true BR112015009070A2 (pt) 2017-07-04

Family

ID=49679267

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015009070A BR112015009070A2 (pt) 2012-10-23 2013-10-18 proteína de fusão ou coquetel de antígenos; uso de uma proteína de fusão ou um coquetel de antígenos; vacina; e método para imunizar um animal, que inclui um ser humano, contra tuberculose causada por microbactérias virulentas

Country Status (8)

Country Link
US (1) US9526773B2 (cg-RX-API-DMAC7.html)
EP (1) EP2912056B1 (cg-RX-API-DMAC7.html)
JP (1) JP6470179B2 (cg-RX-API-DMAC7.html)
CN (1) CN104736555B (cg-RX-API-DMAC7.html)
BR (1) BR112015009070A2 (cg-RX-API-DMAC7.html)
IN (1) IN2015DN03962A (cg-RX-API-DMAC7.html)
WO (1) WO2014063704A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201503467B (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3092000A1 (en) * 2014-01-09 2016-11-16 Transgene SA Fusion of heterooligomeric mycobacterial antigens
WO2015161853A1 (en) * 2014-04-24 2015-10-29 Statens Serum Institut New m.tuberculosis vaccines
WO2017055235A1 (en) * 2015-09-30 2017-04-06 Boehringer Ingelheim Vetmedica Gmbh Improved modular antigen transportation molecules and uses therof in animals
CN105218681B (zh) * 2015-10-21 2019-06-25 中山大学 一种用于诱导外周血单个核细胞产生结核特异性细胞因子的融合蛋白
CN105218680B (zh) * 2015-10-21 2019-06-25 中山大学 一种用于诱导外周血单个核细胞产生细胞因子的结核分支杆菌融合蛋白
CN105567660B (zh) * 2016-01-08 2018-11-20 中国人民解放军第四军医大学 一种大肠杆菌重组表达结核分枝杆菌Rv2837c活性蛋白的方法及其应用
EP3458088A2 (en) * 2016-05-21 2019-03-27 Infectious Disease Research Institute Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
AU2017280065B2 (en) 2016-06-22 2021-07-01 International Aids Vaccine Initiative, Inc. Recombinant cytomegalovirus vectors as vaccines for tuberculosis
EP3555630B1 (en) 2016-12-14 2023-05-31 Becton, Dickinson and Company Methods and compositions for obtaining a tuberculosis assessment in a subject
CA3052084A1 (en) * 2017-01-09 2018-07-12 Biomunex Pharmaceuticals A polypeptide linker for preparing multispecific antibodies
WO2019079155A1 (en) * 2017-10-17 2019-04-25 International Aids Vaccine Initiative, Inc. CASSETTES OF ANTIGENS OF TUBERCULOSIS
WO2020249756A1 (en) 2019-06-14 2020-12-17 Statens Serum Institut Fusion proteins for tuberculosis vaccines
US12599655B2 (en) 2019-08-01 2026-04-14 Trustees Of Tufts College Neisseria gonorrhoeae vaccine compositions and methods of selecting antigens
CN110590958B (zh) * 2019-09-11 2021-04-13 中国人民解放军总医院第八医学中心 一种串联多肽及其在抗结核分枝杆菌的免疫保护中的应用
CN116284283A (zh) * 2021-12-13 2023-06-23 江苏瑞科生物技术股份有限公司 重组结核分枝杆菌抗原、其制备方法和应用
CN118765203A (zh) 2022-02-21 2024-10-11 史坦恩斯血清研究所 一种新型阳离子佐剂组合物
CN115300618B (zh) * 2022-05-11 2026-03-27 中国农业大学 基于牛β防御素5的结核疫苗及其在预防结核病中的应用
CN115184603B (zh) * 2022-06-30 2024-02-06 首都医科大学附属北京胸科医院 EspC蛋白在制备结核分枝杆菌分离或富集产品中的应用
KR20250087737A (ko) * 2023-12-06 2025-06-17 주식회사 미코라파 결핵균에 대한 살균면역을 유도하는 융합단백질을 포함하는 결핵 백신 조성물
CN118108815B (zh) * 2024-04-23 2024-07-23 成都康华生物制品股份有限公司 结核分枝杆菌多免疫原抗原、编码其的mRNA、应用
US20250387462A1 (en) * 2024-06-21 2025-12-25 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and vaccine for the prevention of tuberculosis or other mycobacterial infections
CN121591854A (zh) * 2024-08-14 2026-03-03 首都医科大学附属北京胸科医院 一种结核病mRNA疫苗及其制备方法与应用
CN121591853A (zh) * 2024-08-14 2026-03-03 首都医科大学附属北京胸科医院 一种结核病mRNA疫苗及其制备方法与应用
CN119823286B (zh) * 2025-01-16 2026-02-06 中国动物卫生与流行病学中心 一种重组蛋白抗原及其在制备用于检测牛伽马干扰素试剂盒中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9909472A (pt) * 1998-04-07 2001-09-11 Corixa Corp Polipeptìdeo purificado, processo para prevenir tuberculose, e, composição farmacêutica
DE60236573D1 (de) * 2002-04-05 2010-07-15 Pasteur Institut Identifizierung der Virulenz-assoziierten Regionen RD1 und RD5, die die Entwicklung von verbesserten Impfstoffen mit M. bovis BCG und M. microti ermöglicht
EP2421557B1 (en) * 2009-04-24 2018-12-05 Statens Serum Institut A tuberculosis tb vaccine to prevent reactivation
US20130345079A1 (en) * 2010-10-27 2013-12-26 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity

Also Published As

Publication number Publication date
EP2912056B1 (en) 2020-02-12
WO2014063704A3 (en) 2014-06-19
IN2015DN03962A (cg-RX-API-DMAC7.html) 2015-10-02
JP2015536309A (ja) 2015-12-21
WO2014063704A8 (en) 2015-07-30
ZA201503467B (en) 2016-11-30
CN104736555B (zh) 2019-06-21
JP6470179B2 (ja) 2019-02-13
US20150290311A1 (en) 2015-10-15
EP2912056A2 (en) 2015-09-02
CN104736555A (zh) 2015-06-24
US9526773B2 (en) 2016-12-27
WO2014063704A2 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
BR112016023778A2 (pt) proteína de fusão ou coquetel antígeno, uso de uma proteína de fusão ou coquetel antígeno, vacina, e método para a imunização de um animal, incluindo um ser humano, contra a tuberculose causada por micobactérias virulentas
IN2015DN03962A (cg-RX-API-DMAC7.html)
UA114502C2 (uk) Вакцина mycoplasma hyopneumoniae
WO2016176624A3 (en) Porcine pestvirus, vaccines, and assays
BR112016028816A2 (pt) combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório, e, kit.
BR112014011229A2 (pt) composições e métodos para o tratamento de citomegalovírus
MY173004A (en) Mycobacterial antigen vaccine
BR112016022814A8 (pt) composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico
BR112016015422A2 (pt) formulações de vacina de frasco único
BRPI1013780B8 (pt) Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
BR112021025172A2 (pt) Proteínas de fusão para vacinas de tuberculose
EA201790239A1 (ru) Молекула-носитель для антигенов
WO2006136162A3 (en) Tuberculosis vaccines comprising antigens expressed during the latent infection phase
MX2018013172A (es) Metodos para el tratamiento de las enfermedades en las que es perjudicial la actividad de la il-13, a traves del uso de los anticuerpos anti-il-13.
EA201892568A1 (ru) Способы получения контрастных средств для ультразвукового исследования
BRPI1006452A2 (pt) vacina ou composição imunogênica que é administrada após a exposição a indivíduos com infecção latente que previne a reativação de tuberculose; método para tratar um animal, incluindo o ser humano, contra a reativação da infecção por tuberculose causada por micobactérias virulentas, uso de um antígeno selecionado do grupo
CO2018012506A2 (es) Composiciones farmacéuticas y regímenes de dosificación para el uso clínico de anticuerpos contra el antígeno 2 de las células dendríticas de la sangre
BR112013000345A2 (pt) composições antigênicas para vírus sincicial respiratório e métodos
BR112016016103A2 (pt) Composição de antígenos micobacterianos
MX380411B (es) Sistema de marcadores, en particular para antigenos subunitarios expresados por baculovirus.
MX2016013277A (es) Vacuna para estreptococo de grupo a.
WO2015144732A3 (en) Uses of parasite macrophage migration inhibitory factors
BR112014020025A8 (pt) Vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas
MX388527B (es) Composiciones adyuvantes y metodos relacionados.
AR093530A1 (es) Adyuvante de vacunacion, preparacion, y vacunas que lo contienen

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2640 DE 10-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.